Clinical Trial Update: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating icotinib in patients with Neurofibromatosis Type 2 and related vestibular schwannomas has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type 2
• Vestibular Schwannoma

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Li Peng | Conditions: Vestibular Schwannoma, Neurofibromatosis Type 2 | Phase 2 | Status: COMPLETED